Touro Scholar
Touro College of Osteopathic Medicine
(Middletown) Publications and Research

Touro College of Osteopathic Medicine
(Middletown)

2016

Sepsis: Epidemiology, Pathophysiology, Classification, Biomarkers
and Management
Noah Pirozzi
Nima Rejali
Matthew Brennan
Anuj Vohra
Trevor McGinley

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/tcomm_pubs
Part of the Pathological Conditions, Signs and Symptoms Commons

Recommended Citation
Pirozzi, N., Rejali, N., Brennan, M., Vohra, A., McGinley, T., & Krishna, M. G. (2016). Sepsis: Epidemiology,
pathophysiology, classification, biomarkers and management. HSOA Journal of Emergency Medicine,
Trauma & Surgical Care, 3(1) [Article 014].

This Article is brought to you for free and open access by the Touro College of Osteopathic Medicine (Middletown)
at Touro Scholar. It has been accepted for inclusion in Touro College of Osteopathic Medicine (Middletown)
Publications and Research by an authorized administrator of Touro Scholar. For more information, please contact
touro.scholar@touro.edu.

Authors
Noah Pirozzi, Nima Rejali, Matthew Brennan, Anuj Vohra, Trevor McGinley, and Murali G. Krishna

This article is available at Touro Scholar: https://touroscholar.touro.edu/tcomm_pubs/2

Pirozzi N, et al., J Emerg Med Trauma Surg Care 2016, 3: 014

HSOA Journal of
Emergency Medicine Trauma and Surgical Care
Review Article

Sepsis: Epidemiology, Pathophysiology, Classification,
Biomarkers and Management
Noah Pirozzi1, Nima Rejali1, Matthew Brennan1, Anuj Vohra2,
Trevor McGinley2 and Murali G Krishna2,3*
1

Touro College of Osteopathic Medicine, Middletown, New York, USA

2

Orange Regional Medical Center (ORMC) - Middletown, New York, USA

Division of Pulmonary, Critical Care and Sleep Medicine, Orange Regional Medical Group, Middletown, New York, USA

3

significant amount of the total number of sepsis patients [1]. Similar
to the general population, the elderly also have experienced dramatic
increases in sepsis hospitalizations as shown in table 2 [3]. A more
recent study has shown that sepsis likely contributed between 30 and
50% of mortality and had a large impact on healthcare costs in the
US between 2010 and 2012 [4]. With the growing burden of sepsis on
the healthcare system, there is a strong drive to develop more efficient
mechanisms to detect and manage sepsis patients.
2000 Hospitalization
Rate (per 10,000)

2008 Hospitalization
Rate (per 10,000)

Sepsis as a Primary Dx

11.6

24

Sepsis as any Dx

22.1

37.7

Table 1: Sepsis Hospitalization Trends 2000-2008: Hospitalizations for sepsis
have more than doubled from 2000 to 2008 demonstrating the increasing
burden of sepsis on the US healthcare system [5].

Abstract
Every physician has been trained early in their careers on how
to recognize and manage sepsis. Although sepsis has been one of
the most researched ailments in medicine, it also remains one of the
deadliest diseases in the face of recent advances. In this current
article, we review the diagnostic and management criteria for
Systemic Inflammatory Response Syndrome (SIRS), sepsis,
severe sepsis, septic shock, and Multi Organ Dysfunction Syndrome
(MODS). We then examine the implications of the “surviving sepsis”
campaign as well as explore the philosophy of Early Goal Directed
Therapy (EGDT) and its role in the modern day management of
sepsis. In addition, we sought to highlight potential new biomarkers
and current available therapies in sepsis.

Introduction
Sepsis continues to be a critical problem in regards to morbidity
and mortality in the clinical setting. Ranked as a top cause of
morbidity and mortality, sepsis can be the result of a number of
pathologies and can greatly complicate the care of patients in and out
of the hospital setting [1]. Despite advances in the treatment of sepsis,
28 day in hospital mortality rates still range from 15 to 45% [2].

Epidemiology
Inpatient expenses related to the treatment of sepsis infections are
on the rise with annual costs estimated to be in excess of $20 billion
[3]. This places sepsis as one of the most costly burdens on the health
care system. Sepsis rates are on the rise (Table 1) [4]. The elderly
population is at a greater risk for the development of sepsis and
sepsis related complications. As a result this population makes up a
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Age Group

2003 Sepsis Hospitalization
Rate (per 10,000)

2007 Sepsis Hospitalization
Rate (per 10,000)

18-64

8.3

13

65-84

64.7

99.8

85+

177.1

219.7

Table 2: Age specific Sepsis Hospitalization Rates in USA. Hospitalization
rates increased dramatically in the 5 year span. The rates increased dramatically in all age groups over the short 5 year period [3].

Mortality
Mortality rates for sepsis in recent years have ranged from 18 to
40%. The identification of the correct microbial strain and initiation of
the proper antibiotic treatment could significantly affect the incidence
of mortality in these patients. The highest incidences of mortality are
associated with sepsis arising from nosocomial infections by
organisms such as methicillin resistant and sensitive staphylococcus
species, pseudomonas and both candida and non-candidal fungal
infections. Polymicrobial infections are also associated with increased
mortality rates [6].
Biomarkers currently used in the identification and management
of septic patients can provide insight into the response to therapy and
prognosis. Although using biomarkers to rule in sepsis have not been
identified with strong support, Lactate level measurements have been
the greatest focus in recent years and have been shown to correlate
well with mortality [7]. Lactate levels greater than 4.0 mmol/L have
been shown to correlate with an increase in mortality. In addition, this
correlation is even stronger if there is a coexistence of elevated lactate
with observed hypotension [7]. Other sources have found correlations
with 48 hour resolution of elevated lactate levels and sepsis prognosis
[8].

Pathophysiology
Sepsis and disease severity depend on various factors, ranging
from the properties of the invading pathogen to the current immune
status of the host [9]. Severe sepsis can develop following local
infection and can stem from a number of sites including the abdomen,
skin, soft tissue, urinary tract, lungs and is usually due to a primary
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bloodstream infection. The pathophysiology of sepsis can be
initiated by the host response to a pathogen insult, particularly the
outer membrane component of gram negative organisms such as
Lipid A component of LPS (Lipopolysaccharide), also known as
endotoxin or components of gram positive organisms such as
lipoteichoic acid and peptidoglycan. Sepsis can also be triggered by
viral, fungal, and parasitic components. The innate immune system
is the first line of defense, which includes the monocytes and
dendritic cells, which recognize various pathogens based on their
pathogen recognition receptors. Through interaction of pathogenic
components via signaling of Toll like Receptors on monocytes,
the transcription factor NF-κB is activated and important pro-inflammatory cytokines are generated such as TNF-alpha and IL-1.
These inflammatory cytokines then lead to production of mediators
such as prostaglandins, leukotrienes, platelet-activating factor and
phospholipase A2 which leads to increased vascular permeability
and vasodilation. TNF-alpha and IL-1 also lead to the production of
adhesion molecules such as E and P selectin that eventually leads
to neutrophil recruitment and further endothelial injury through
neutrophil components, particularly nitric oxide, which is a potent
vasodilator which leads to septic shock [9]. Activated neutrophils also
promote clearance of the bacteria. While beneficial, this process in
turn can do more damage by contributing to more inflammation via
respiratory burst, cytotoxicity, degranulation, vascular permeability
and organ injury. Many sources of literature cite this massive trigger
of inflammation as the “cytokine storm” [9].
The adaptive immune system as well, plays an active role. The
adaptive immune systems also attempt to attenuate the harmful effects
of the proinflammatory state. For example, regulatory T cells produce
various mediators such as IL-10 and TGF-beta to reduce
inflammation. The complement cascade is also activated by
microbial components leading to production of anaphylatoxins,
chemotactic fragments and opsonins all of which lead to a
proinflammatory state. Microbial components can also activate
coagulation by activating factor XII of the coagulation cascade
or indirectly through changing the endothelium function. The
continual pro-inflammatory state also activates immunosuppressive
mechanisms, leading to oscillations between hyper-inflammatory and
immunosuppressive states during the clinical course of the disease.
Some mechanisms propose that there is a shift towards a Th2
(anti-inflammatory) response from a Th1 (pro-inflammatory)
response [9]. With complement activation and coagulation cascade,
micro-vascular blood flow may be compromised which will result
in local ischemia, ultimately leading to global tissue hypoxia and
insufficient oxygen delivery to meet oxygen demands of the
body. This can lead to metabolic acidosis, hypotension, impaired
myocardial contractility, multi-organ dysfunction syndrome and
death [9].

Classification
Sepsis is defined as a systemic illness where bacteria enter a
normally sterile place in the body. The definition takes evidence of
Systemic Inflammatory Response Syndrome (SIRS) and incorporates
it with suspicion of a microbial origin. When this criteria includes
acute organ dysfunction of at least one organ, this becomes severe
sepsis. Further dysfunction accompanied with refractory hypotension
or hypoperfusion, while fluid resuscitation is being attempted,
classifies as septic shock. Finally, when organ dysfunction
progresses to the point where the patient is unable to maintain
homeostasis without intervention it’s called Multi-organ Dysfunction
J Emerg Med Trauma Surg Care
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Syndrome (MODS). The creation of a staging system for sepsis has
allowed for a goal driven therapy to improve out comes [6].
Classification

Parameter

Systemic
Inflammatory
Response Syndrome
Sepsis

Core body temperature >38°C or <36°C HR ≥90
bpm Respirations ≥20/min (or PaCO2 <32 mmHg)
WBC ≥12,000/μl or≤4000/μl or >10% immature
forms
At least two SIRS criteria caused by known or
suspected infection

Severe Sepsis

Sepsis with acute organ dysfunction

Septic Shock

Sepsis with persistent or refractory hypotension
or tissue hypoperfusion despite adequate fluid
resuscitation

Multi-Organ
Dysfunction Syndrome

The presence of organ dysfunction in an acutely ill
patient such that homeostasis cannot be maintained
without intervention.

Table 3: Classification of Sepsis [6].

Sepsis can be caused by a variety of pathogens. The classification
of sepsis is typically described as either community-acquired or
nosocomial in origin. They can be bacterial or fungal in etiology. In
addition, infections are not mutually exclusive and polymicrobial
infections can and do occur. Within the bacterial causes of severe
sepsis, there is some controversy as to the primary causative agents.
Different epidemiological studies have found both gram negative and
gram positive organisms to be of the greatest cause. Historically the
gram negative organisms were of the greatest prevalence, however;
data has shown an increase in incidence of gram positive infections
in recent years [6]. Of the gram positive organisms, Staphylococcus
aureus and Streptococcus pneumoniae are the most common
organisms found. Of the gram negative organisms, Escherichia coli,
Klebsiella and Pseudomonas aeruginosa are found in the greatest
numbers [10].

Risk factors
There are many risk factors associated with sepsis and severe
sepsis. Most of these factors relate to a patient’s ability to fight
infection and the probability that acute organ failure develops in
response to infection. In general, greater risk is associated with male
gender, black race, age, and chronic health conditions. Age arguably
might be the most important risk factor to consider. As patients age
the incidence of severe sepsis increases disproportionately to the point
where patients over the age of 65 years old account for more than
50% of severe sepsis cases [11]. On the other end of the age spectrum
neonates have a high incidence of severe sepsis and septic shock as
well compared to the total population. Estimates attribute over 36%
of all neonatal deaths to cases of neonatal sepsis worldwide [6].
Immature immune systems and early exposure to various microbial
agents, including those stemming from maternal sources, have made
neonatal sepsis potentially dangerous complication in this population
with case fatality rates ranging from 7% to 25% [12]. Group B
Streptococcal, and to a lesser degree E coli, infections appear to
comprise the majority of cases with early onset. In later onset
cases the causative agent is more likely to be coagulase negative
Staphylococcus species and Staphylococcus aureus are the most
common causative agents [12]. More than half of patients who present
with severe sepsis have at least one chronic health condition
concurrently. The most common chronic conditions are immune
insufficiency (primary or secondary), cancer, chronic obstructive
pulmonary disease, chronic renal disease, diabetes, and chronic
liver disease. Situational risk factors include immunosuppressive
Volume 3 • Issue 1 • 100014
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drugs, malnutrition, prosthetic devices, and residence in long term
care facilities. Of note, environmental factors such as cold weather
coincide with greater occurrence of severe sepsis and increased
mortality despite a similar severity of illness [11].

Diagnosis
Sepsis is a disease that is classified by a wide variety of clinical
presentations. It is important to mention the proper screening with
a goal of early detection for better patient outcomes. Early detection
is key for better patient outcomes which have been accomplished by
the creation of screening tools. Patients who are already admitted for
severe infections should be screened routinely for sepsis using the
diagnostic criteria mentioned. It is imperative that these patients are
diagnosed early to allow for the early implementation of therapy.
There has been Sepsis screening tools developed for ICU care that
assist in this process. It should be of the utmost importance to reduce
the time to diagnosis in all patients.
If there is clinical suspicion of an infection being the etiology of
septic shock, there should be no delay in the prompt treatment with
antimicrobials. Two or more blood cultures should be drawn once
there is access to initiate treatment and more directed antimicrobial
therapy for later on. Blood cultures should be drawn from peripheral
sites, not from existing IV access and care should be taken that they
are filled properly (>10ml of blood). If cultures prove to be positive
from vascular access site, earlier than peripheral blood site this would
suggest vascular access as the point of entry [6]. Ideally, Cultures of
IV and catheters should also be taken with peripheral blood smears to
help determine the source of infection [6].
Gram stain is also a useful tool, most commonly for respiratory
tract specimens, with positive cultures for lower respiratory tract
infections. Simultaneously, tests such as Rapid influenza antigen should
be used during proper seasons for additional information. As with
most diagnoses a focused history is a crucial source of information.
Use of the 1,3 Beta, D-glucan assay, mannan and anti mannan assay
has proven useful for the early diagnosis of systemic fungal
infections of which the usual culprit is invasive candidiasis [6].
However, it should be noted that false positives are possible with
colonization alone, and more study is needed. Thorough analysis of
specimens is required. It has been shown that a delay in treatment has
adverse outcome for patients with sepsis. Therefore, it is imperative
that clinical suspicion should be taken seriously as patients fall into
parameters associated with sepsis. The clues involved can be put into
5 different categories. Each of these categories should be considered
when an infection is documented or suspected [6].
a. General variables
• Fever > 38 degrees C
• Hypothermia core temperature <36 degrees C
• Heart rate >90/min or more than two SD above the normal
value range
• Tachypnea
• Altered mental status
• Significant edema or positive fluid balance > 20 mL/kg
over/24hr
• Hyperglycemia plasma glucose >140 mg/dL or 7.7 mmol/L in
the absence of diabetes
J Emerg Med Trauma Surg Care
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b. Inflammatory variables
• Leukocytosis WBC >12,000/microL
• leukopenia WBC count < 4000/uL
• Normal WBC count with greater than 10% immature forms
(shift to left)
• Plasma C reactive protein more than 2 above normal value
• Plasma procalcitonin more than 2 above normal value
c. Hemodynamic
• Arterial hypotension Systolic Blood Pressure <90 mmHg,
Mean Arterial Pressure <70 mmHg or a decrease in systolic
blood pressure >40 mmHg in adults or less than two SD below
normal for age.
• Organ dysfunction
• Arterial hypoxemia Pao2/Fio2 <300
• Acute Oliguria urine output < 0.5 mL/kg/hr for at least 2 hrs
despite adequate fluid resuscitation
• Creatinine increase > 0.5 mg/dL or 44.2 micromol/L
• Coagulation abnormalities INR >1.5 or aPTT > 60s
• Thrombocytopenia platelet count < 100,000/microL
• Hyperbilirubinemia plasma total bilirubin > 4 mg/dL or 70
micromol/L
d. Tissue perfusion variables
• Hyperlactatemia >1mmol/L
• Decreased capillary refill or mottling
In some institutions these variables and also specifically the
criteria as associated with the classification of sepsis are used in
electronic medical records to trigger alerts and help with a timely
diagnosis.

Biomarkers
Biomarkers, although important in many other clinical diagnoses,
have not been thoroughly studied and if used have the greatest efficacy
in ruling out sepsis diagnoses. Further studies must be made into
biomarkers for the early detection of sepsis as well as their use
prognostically. Two biomarkers have been studied in adults for the
early diagnosis of sepsis with a sensitivity and specificity greater than
90% with a high positive predictive value. Group II phospholipase 2
(PLA2-II) has been studied in brief with a high sensitivity and
specificity for bacteremia in adults within 24 hours of admission.
Although there was a high sensitivity and specificity for early
diagnosis with CD64 it was unable to distinguish local from systemic
infection and bacterial from viral infections [13]. It seems the CD64
also know as Fc gamma RI which is displayed on neutrophils and
monocytes, is more indicative of febrile infection.
As stated before, currently biomarkers have the greatest use
clinically as means to rule out sepsis. Both CD64 and PLA-II are
research phase markers that may or may not show clinical application
in the future [13]. Although there is data supporting the use of PCT to
differentiate infectious from noninfectious forms of SIRS, it should be
noted, as with most diagnoses, that biomarkers should only aid in the
diagnosis. All of the aforementioned biomarkers were studied in only
culture positive sepsis, further showing a weakness in the diagnostic
value due to the possibility of culture negative sepsis [14].
Volume 3 • Issue 1 • 100014
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C-Reactive Protein

Antimicrobials

C-Reactive Protein (CRP) is an acute phase reactant and
biomarker used for tracking inflammation in response to infection
and tissue injury. Although it is possible to aid in the diagnosis of
severe sepsis, CRP is also elevated in the following conditions: late
pregnancy, active inflammation, bacterial infections, viral infections,
and elderly age. The specificity of CRP testing in severe sepsis and
the use of CRP to track sepsis progression has never been proven.
However, since severe sepsis is an inflammatory state, it follows that it
should be used to create a picture in septic patients [15].

Studies have shown that delay in the administration of
intravenous antibiotics increased mortality. Antimicrobial therapy
should be administered within the first hour of the recognition of
severe sepsis or septic shock. This initial treatment should consist
of one or more drugs that have activity against all likely pathogens
(bacterial and/or viral) and at concentrations that have the ability to
penetrate the tissues of the supposed point of entry or source of the
sepsis. Anti fungals should only be used in those at risk of invasive
fungal species. Treatment should also be directed based off of the
setting in which the infection was developed and medical history [6].

Procalcitonin
Procalcitonin has been intensely studied in recent years and has
had some positive feedback clinically. Studies have been done showing
PCT to be of use in tracking the severity of sepsis in general (without
any guidelines as of yet) with evidence of peak PCT levels immediately
before death due to MODS [16-18]. Although it should be said that,
most studies that showed this result were associated with severe sepsis
secondary to burn injury. The most recent edition of Surviving Sepsis
Campaign states that using PCT to differentiate acute inflammation
from severe sepsis has not been demonstrated to be useful as of yet [6].
There is also a role for PCT to help guide antimicrobial therapy which
has not been demonstrated to reduce mortality or morbidity but does
offer less exposure of ICU patients to antimicrobials. Low PCT levels,
along with other clinical factors, may aid in early discontinuation of
antimicrobials [6,19]. Procalcitonin (PCT) level is currently the most
reliable biomarkers due to its strong negative predictive value

Management
The “Surviving Sepsis Campaign” is an international coalition of
experts that developed categorical recommendations and suggestions
on the resuscitation of patients experiencing septic shock. From this
was created two “bundles” of care; one to be instituted within 3 hours
and another within 6 hours.
The first bundle is to be achieved within 3 hours of the
identification of severe sepsis. At initiation of the protocol,
baseline lactate levels should be obtained for later comparison
and to get a sense of the patient’s current perfusion status. Blood
cultures should also be drawn at this time for a more directed
antimicrobial treatment plan, if possible, once resulted. To start
treating the underlying cause broad spectrum antimicrobials will
lay the framework for long term treatment. Finally, if the patient has
a lactate greater than or equal to 4 mmol/L or hypotension at the
time of presentation, they should be administered 30 ml/kg of
crystalloid solution, where the time of presentation is defined as the
time of triage in the emergency department or the earliest record of all
the elements consistent with severe sepsis or septic shock [6].
The second phase, to be completed within 6 hours, is to place a
monitor and possibly adjust the previously started treatment. To
start, fluid responsiveness should be assessed by methods noted
in the hemodynamic resuscitation section. Patients, who cannot
maintain a Mean Arterial Pressure (MAP) greater than 65 mmHg
after an attempt at hemodynamic resuscitation, should be treated with
vasopressors to prevent further hypotension. If hypotension persists
(MAP less than 65 mm Hg) or if the baseline level of the drawn lactate
was greater than 4 mmol/L volume status and tissue perfusion should
be assessed again and the findings documented in accordance with
table 1 diagnostic criteria. After this the lactate should be measured
again if the initial lactate was elevated [6].
J Emerg Med Trauma Surg Care
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Reassessment of the patient after 6 hours should focus on
monitoring and supporting organ function, treatment of
complications, and careful de-escalation of care. This is in
conjunction with the monitoring of lactate and other pertinent
biomarkers to guide therapy. Empiric broad spectrum antibiotic
therapy should not be continued for more than 3-5 days to prevent
the emergence of resistant microbial species, minimize drug toxicity,
and to reduce costs. Once cultures have returned their susceptibility
profiles, targeted therapy should be initiated. The duration of therapy
should normally not take more than 7-10 days barring a slow clinical
response to therapy, immunodeficiency and infection with S. aureus,
fungal infections and some viral infections [10].

Corticosteroid therapy
The use of corticosteroids in the treatment of septic patients has
proven to be quite controversial. The presence of glucocorticoids
whether endogenous or exogenous is essential for control of the host
inflammatory response. Almost unanimously, studies have shown
high dose steroid regimen increases morbidity and mortality in
patients with severe sepsis and in septic shock [20]. The question
remaining is the efficacy of low dose treatment on sepsis outcomes.
Low dose corticosteroid therapy is generally considered to be below
300 mg/day [20]. Mortality rate has been shown to improve with
the use of low dose corticosteroid therapy [21]. A number of studies
showed 28 day mortality rates ranging from 10% to 30% below those
of control groups [20]. In addition multiple studies have found that
low dose corticosteroid treatment of septic patients significantly
improved hemodynamic status through an increase in blood
pressure and decreased duration of pressor usage [20,22]. Other
studies have found no efficacy toward corticosteroid administration
or found increased mortality [23,24]. Those observed to have the most
benefit from therapy also were found to have adrenal insufficiency.
The Surviving Sepsis campaign recommends use of corticosteroid
therapy only in the presence of septic shock and only following a
failure of blood pressure response to pressor and fluid therapies. The
Surviving Sepsis campaign recommends hydrocortisone administration at 200 mg/day in these patients and gradual tapering off once
pressor therapy is no longer needed to maintain adequate blood
pressure [6].

Hyperglycemia management
Septic shock has a tendency to raise blood glucose level. This
effect is also present in various other illness and/or stressors and is
collectively called “stress hyperglycemia”. It was thought initially that
intensive management of glucose was the best route to take and the
surviving sepsis guidelines in 2008 recommended that glucose be kept
between 80-100 mg/dl [25]. However, it was noted by many medical
institutions that this aggressive insulin management was leading to
Volume 3 • Issue 1 • 100014
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marked hypoglycemia [26]. Researchers began to question whether
the hypoglycemia induced by aggressive insulin therapy was more
detrimental than maintaining the patient at a more normal
physiologic glucose level. This is where the NICE-SUGAR study
comes to our attention. This trial is the largest randomized control
trial to date and looks at 2 populations of patients: those with
aggressive insulin management and those with conventional
management [27]. The investigators found that ICU patients in the
aggressive insulin therapy group showed an increased in 90 day
mortality in comparison to their conventional counterparts [27].
The investigators consequently recommended that keeping glucose
levels below 180 mg/dl lowered mortality in comparison to tight
management of the patient at a glucose level of 81 to 108 mg/dl [27].
Surviving sepsis was consequently updated and its 2012 publication
recommended keeping patients below 180 mg/dl but no lower limit
was set except for the avoidance of hypoglycemia and the avoidance of
wide swings in glucose levels [6].

Hemodynamic resuscitation
In the landmark 2001 paper by Rivers et al., the authors recognize
several factors which are paramount to EGDT. These factors include
physical findings, vital signs, central venous pressure, and urinary
output [28]. Having these values are key to early detection and the
start of rapid management to decrease mortality, but individually they
do little to address and determine the level of global tissue hypoxia.
A far better indicator of the patient’s hypoxia and condition is the
observation and response of cardiac output to medical intervention
[29]. By manipulating preload, arfterload, and contractility, the
medical team can better perfuse vital organs and prevent the
degradation of sepsis to septic shock and/or MODS [30]. The gold
standard for such intervention revolves around fluid resuscitation and
pressor therapy. Given the pharmacologic side effects of vasopressors,
fluid therapy is usually considered first line. However, if a patient
is not fluid responsive, then pressors are preferred as further fluid
infusions will present its own set of issues such as edema, pleural
effusions, high blood pressure, and acute renal failure [31]. Following
surviving sepsis guidelines, Nor-epinephrine should be considered
first line at a dose of 0.01-3 mcg/kg/min IV infusion [6]. Adjunctive
therapy can include the use of 0.03 units/minute of Vasopressin to
help improve perfusion. Epinephrine is considered a second line
vasopressor but can also be added to Nor-epinephrine therapy, if
Nor-epinephrine alone cannot maintain a MAP of 65 mm Hg [6].
Fluid responsiveness is a large part of sepsis management and
currently also one of the most researched topics in regards to reducing
mortality. Patients are considered “fluid responsive” if fluid
resuscitation alone improves the blood pressure [32]. After adequate
replacement of intravascular volume, further infusion of fluid can
adversely affect their hemodynamics. With fluid therapy used initially
to improve tissue perfusion, it becomes imperative to identify whether
patients are fluid responsive or unresponsive. Those that are not responsive to fluid therapy would then be candidates for pressor therapy. The
desired effect of fluid therapy revolves around improving stroke volume
and cardiac output. By increasing pre-load, there can be more filling of the
ventricles and consequently greater contractility via the Frank-Starling mechanism. Patients are defined as “Fluid-responsive” and
“Non-responsive” depending on the degree of hemodynamic
improvement in response to initial fluid bolus defined as an increase
in stroke volume of 10-15% [32]. It has been proposed that heart-lung
interactions can also be used to determine fluid responsiveness and
in 2000 Michard, Pinsky, and Teboul published the caval index to be
J Emerg Med Trauma Surg Care
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used on patients as a marker of fluid responsiveness [22]. The Caval
Index is defined as;
Caval Index = (IVC-exp diameter - IVC insp diameter) / (IVC-exp
diameter) * 100
A normal IVC diameter is 1.5-2.5 cm and if there is a less than
50% collapse of the IVC, this suggests fluid overload [33]. This type
of patient would not benefit from fluid therapy and in fact can be
harmed from hyperperfusion. By using ultrasonography to measure
IVC diameter, we can determine a patient’s response to fluids without
invasive methods such as swan ganz catheter or CVC.
Another non-invasive tool used to assess fluid responsiveness is
the passive leg raise test. Due to the large compliance of the venous
system, the human body has a tendency to pool extra blood volume in
the legs where the effects of gravity and compliance are felt the most.
Physicians can utilize this physiological occurrence to guide their
route of management. The technique is best done with the patient flat
on their back with their feet propped up to 45 degrees. 30-90 seconds
in this position is enough to replicate the effects of a 250cc bolus of
fluids as blood is being returned to the effective circulation and
causing an increase in preload [34]. There are many methods to
measure the effects of this pseudo-bolus including stroke volume
index via a cardiac output monitor or through a surrogate
measurement such as pulse pressure via arterial line. Another way
to measure this response to fluids would be to utilize the same
ultrasonography techniques as used to measure the IVC and calculate
the caval index as mentioned above.
Each method has a set of advantages and disadvantages and it
is up to the physician to determine which method is most likely to
aid in their initial management of the patient. Invasive measures are
best reserved for patients who already have a CVC and/or are being
managed in the ICU under constant monitoring. Patients however
who present acutely to the ED stand little benefit in going directly to
invasive cardiac monitoring to assess fluid response. The major caveat
here of course would be if the physician in unable to attain peripheral
IV access and a CVC needs to be placed to gain circulatory access.
However, in most cases, patients arriving to the ED would be better
candidates for non-invasive measurements of fluid responsiveness via
ultrasonography of the IVC before and after an initial trial fluid bolus
or a passive leg raise test.

Recent Advances
EGDT in clinical trials
Trials in recent years have looked to assess the effect of early goal
directed therapies and standardized treatment bundles on sepsis
outcomes. These various studies have yielded mixed results. The
Surviving Sepsis Campaign treatment bundles were largely based off
of the 2001 Rivers paper [28]. This study was one of many that found
improved health outcomes with the implementation of a set protocol
aimed at achieving a few key goals. These studies, demonstrating
efficacy of treatment bundles and early goal directed therapies,
all showed their value through observed reductions in mortality
[24,35-37].
Other studies, primarily the United States’ ProCESS, United
Kingdom’s ProMISe and the Austrailasian ARISE studies, failed to
find significant reductions in mortality following implementation
of EGDT modalities and treatment bundles. These studies,
following study protocols based on the 2001 Rivers paper, found
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potential benefits of EGDT not directly associated with mortality. Not
surprisingly these three studies found that following implementation
of set protocols patients were more likely to receive therapies
included in the treatment bundles [38-40]. The ProCESS trial found
an increase in length of hospital stay while the ProMISe trial found
patients were more likely to receive higher levels care for sepsis
[38,39]. The ARISE Trial interestingly found a decrease in the average
time for sepsis patients spent in the Emergency Room offering
another potential benefit [40]. The mix in results of these studies
makes it difficult to definitively determine the benefits of EGDT and
bundle set treatment modalities in sepsis. At this point it appears more
research is needed to make definitive conclusions.

paper and those outlined by the Surviving Sepsis Campaign, should
be credited with the observed drop in mortality. More research is
needed to fully understand the efficacy of treatment bundles and
identify the important components that should be included in them.
We the authors feel the greatest potential in future management of
sepsis patients is in the development of new biomarkers and improved
methods in the assessment of fluid responsiveness. Additionally,
there should be a continued push towards mastering non-invasive
monitoring techniques and matching the sensitivity and accuracy of
these techniques to those of current more invasive practices.

NICOM

1. National Center for Health Statistics (2015) Health, United States, 2014: With
Special Feature on Adults aged 55-64. Hyattsville MD, USA.

As sepsis therapy progresses, there is a push to continue to find
non-invasive alternatives rather than relying on highly invasive
methods of management such as PICC lines, CVC, and/or Swan Ganz
catheter. Of specific interest to recent advances is the Non-invasive
Cardiac Output Monitoring (NICOM) machine. The NICOM
machine works by measuring the phase shift between superior
thoracic leads and inferior abdominal leads. The machine elicits an
alternating current in the upper thoracic leads where it then travels
down through the vasculature and tissue to the lower leads, a process
called “bioreactance” [41]. The phase shift is dependent largely on the
volume of fluid in the large thoracic vasculature. By measuring the
phase shift of the electrical impulses the machine calculates the stroke
volume. The electrodes of the machine are also capable of monitoring
heart rate. By taking the heart rate and stroke volume into the account,
the machine provides real time feedback about cardiac output.
There is still more research required to determine whether this
method of monitoring is as reliable as inspiratory IVC diameter
ultrasonography as well as the IVC diameter measurements before
and after passive leg raise test. A few preliminary research studies have
shown promise in the sensitivity of NICOM related to other currently
accepted, yet invasive therapies [42-45]. Until further trials can prove
the efficacy of this device in contrast to time tested gold standards like
those mentioned previously, the NICOM machine will need to remain
in a trial only phase before it can be rolled out to hospitals worldwide.
There is certainly no harm in using it on patients as an added modality
while still maintaining other methods to assess fluid response. This
is exactly what is occurring at medical centers currently conducting
clinical trials with the NICOM, but at this point the device should not
be used as an end all for patient cardiac output monitoring.
Yet, the machine holds much promise in the future management of
sepsis patients, particularly in the realm of fluid management. While
using Ultrasonography requires testing before and after a therapy is
given (i.e., fluid bolus), NICOM can be left on the patient and give
medical teams real time feedback on the patient’s cardiac output and
fluid responsiveness. To the patient’s advantage particularly is the
ability of this device to do all this in a non-invasive method and
without cumbersome devices and modalities such as repeated
ultrasounds and there is also reduced risk of nosocomial infections.

Conclusion
Severe sepsis and septic shock while heavily researched; still impose
a huge burden on patients and the healthcare system. While mortality
rates have dropped in recent years, overall hospitalizations for sepsis
have increased. Studies have been split on whether the establishment
of protocols, like the EGDT series introduced in the Rivers 2001
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